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SUMMARY
Background
CDEUSSA is a Specific Support Action project from the Sixth Framework
Programme Priority of the European Union (EU). Its aim is to bring
together basic and applied research in the area of coeliac disease (CD). This
paper reviews the main issues that are a result of the CDEUSSA initiative.
Aim
To identify the major issues in need of investigation in the areas of
clinical aspects, treatment, prevention and public health.
Methods
Key stakeholders, representing a wide range of knowledge with crucial
importance for CD research and practice, have participated in two work-
shops aimed at identifying and proposing to the EU, as high priority
research, topics in the areas of clinical aspects, treatment, prevention
and public health.
Results
In public health, the overall goal should be to improve quality of life of
the European population by implementing primary prevention strate-
gies, early diagnosis and improved treatments for CD. New treatment
strategies need to be developed. The option of primary prevention
should be fully explored, which requires combined epidemiological,
clinical and basic scientific research efforts. Such studies should also
consider the importance of gene–environment interactions in the deve-
lopment of CD. Increased knowledge is needed on the natural history of
CD. Diagnostic criteria need to be revised.
Conclusions
To achieve these goals, a collaboration of the stakeholders is fundamen-
tal, including research and patient organizations, as well as industries
within both diagnostics and food production.
Aliment Pharmacol Ther 27, 1030–1043
Alimentary Pharmacology & Therapeutics
1030 ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd
doi:10.1111/j.1365-2036.2008.03668.x
INTRODUCTION
Coeliac disease (CD) is generally defined as a gluten-
dependent enteropathy, but is actually a multiorgan
inflammatory disorder with large negative health con-
sequences for many of those affected. It is not, as pre-
viously thought, a rare disease of childhood, but can
have its onset at any age, and has lately emerged as a
worldwide public health problem.
CD has a multifactorial aetiology. With regard to
disease development, both genes and the environment
and interactions between the two of them influence
immunological responses and may confer either
increased or reduced CD risk. CD has a genetic basis,1
illustrated by family clustering with a prevalence of
about 10% in first-degree relatives2 and a 75% con-
cordance in monozygotic twins,3 a rate higher than in
any other condition with a multifactorial basis. The
principal determinants of genetic susceptibility are the
highly variable human leukocyte antigen (HLA) class
II DQA and DQB genes located in the major histocom-
patibility complex at chromosome 6. The combination
of HLA-DQA1*0501 and DQB1*02 alleles encode the
HLA-DQ2 class II protein molecule, which presents
gluten peptides to CD4 positive cells.4 However, it is
clear that additional factors are critical for the devel-
opment of CD as up to 30% of persons of North
European ancestry, most of whom eat wheat, express
HLA-DQ2, but CD develops in only a small proportion
of these carriers. Altered processing of gluten by intra-
luminal enzymes and changes in intestinal permeabi-
lity precede the activation of innate and adaptive
immune responses.
Considerable research has been devoted to CD over
the last decades. CDEUSSA is a Specific Support
Action project from the Sixth Framework Programme
Priority of the European Union. Its aim is to bring
together basic and applied research in the area of CD.
The CDEUSSA process was initiated by selecting and
inviting key stakeholders representing a wide range of
knowledge with crucial importance for CD research
and practice. Thereafter, the call to join has been open
with the aim to expand successively the platform to
ensure representation of a wide range of stakeholders
and to increase its usefulness also in future exchange
of information. CDEUSSA now forms a platform,
mobilizing key stakeholders from research, the food
industry, the European public health field and patient
associations. So far, 103 professionals from 27 coun-
tries, representing a large range of organizations and
disciplines, have adhered to the CDEUSSA initiative.
More information on CDEUSSA is available on the
web (http://www.cdeussa.com). As part of the process,
two workshops were organized in 2006 and partici-
pants identified four CD topics – clinical aspects, treat-
ment, prevention and public health – that need to be
investigated during the next few years. These research
areas and related topics have been proposed to the
European Union as high priority research to improve
the health status of the European population. This
paper reviews the main issues that emerged during the
two workshops, and is thus a result of the CDEUSSA
initiative.
CLINICAL ASPECTS
Elucidation of the clinical and histological
spectrum
It is now widely accepted that CD represents a wide
spectrum of clinical presentations and small intestinal
mucosal changes. Typical clinical manifestations of
CD include chronic diarrhoea, weight loss and anae-
mia. However, a significant proportion of patients
present with extra-digestive symptoms, including skin
lesions, isolated hypertransaminasaemia, bone pains
and fractures, infertility, aphthous ulceration, ataxia
or polyneuropathia.5, 6 It is worth noting that there
are also subjects with no or negligible symptoms
(silent coeliac patients), but still with a small intesti-
nal mucosa with villous atrophy. The suboptimal
medical awareness of the very variable clinical pre-
sentation of CD is an important factor in the lack of
recognition and underdiagnosis of the disease. In
Finland, an education campaign among the health
care professionals has resulted in 50% of diagnoses
among individuals with CD, whereas in most Euro-
pean countries and the US, only 10–20% have been
diagnosed.7 Similar initiatives should be undertaken
in other countries to increase the recognition of the
disease and to improve the health of the patients by
case finding.8
The pathomechanisms underlying the different
manifestations of the disease remain to be clarified.
With the demonstration of deposits of IgA antitrans-
glutaminase in different organs,9 and with the emerg-
ing demonstration of their biological activity,10 the
possibility that some of these clinical manifestations
are the result of an autoimmune insult is more than a
hypothesis.
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The pivotal work of Marsh11 has shown that gluten-
induced pathology can range from very mild (only
intraepithelial lymphocyte infiltration) to different
degrees of villous atrophy depending on several fac-
tors, including the time after challenge and the
amount of gluten. Approximately 10% of children
with serum antiendomysial antibodies undergoing
intestinal biopsy have no villous atrophy (potential
coeliac patients). On immunohistochemical analysis of
these serologically positive patients, inflammatory
signs are mild.12 It is unclear whether their low
inflammatory indices are genetic, perhaps because of
lack of non-HLA predisposing gene(s), or if environ-
mental or immunological factors play a role. In this
group, there are also patients who become ‘seronega-
tive’. The identification of markers predicting if this
lesion will proceed to enteropathy would be very rele-
vant.
Autoimmunity
CD can be considered an autoimmune disease because
of the presence of autoantibodies in both the serum
and the intestinal mucosa.13 However, the biological
consequences of anti-tissue-transglutaminase autoanti-
bodies in the coeliac intestinal lesions are not yet elu-
cidated. Of note, CD is also associated with
concomitant autoimmune disease, approximately 5–10
times more than in the general population. The whole
spectrum of autoantibodies associated with CD and the
mechanisms by which they are induced on a gluten-
containing diet and disappear on exclusion diet need
clarification. These studies have a general relevance to
understand the biological basis of autoimmunity, as
CD is a unique model of autoimmunity where the trig-
ger is well identified. The association of CD with a
number of other autoimmune conditions is the result
of a common genetic background as suggested by
HLA (HLA-DQ2 ⁄8) and non-HLA genes14, 15 shared
with other autoimmune diseases. Gluten as such may
play a role; in fact, emerging clearly is the role of
feeding in the first year of life namely, the time and
amount of gluten ingestion as risk factor for the
development not only of CD but also of other auto-
immune diseases, such as type 1 diabetes mellitus.16
Definition of the natural history
The definition of the natural history of CD is a cru-
cial issue, which demands active investigation. The
identification of the time by which a great majority of
susceptible individuals develop CD-associated autoan-
tibodies is important for the definition of the time
of possible mass screening strategies. A US study of
at-risk, HLA-DR3+ individuals demonstrated a high
prevalence (1:100) of CD-associated antibodies at the
age of 5 years, suggesting that ‘seroconversion’ can
occur quite early in genetically predisposed individu-
als.17 Importantly, Simell et al.18 demonstrated sero-
conversion already at the age of 1.3 years with
another 1% annual conversion at least until age
6 years, but with half of them normalizing without
any dietary manipulation. Such long-term follow-
up studies could also be used to find out the
environmental and life style factors contributing to
the development of the disease and conditioning the
severity of the histological and clinical picture. Also,
the typical life-course pattern with respect to health-
related quality of life (HRQOL) and complications
needs to be mapped for CD cases, taking into account
differences with respect to the degree of small intes-
tinal mucosal changes. In such long-term follow-up
studies, several other factors should also be taken into
account, such as if a subject is treated with a gluten-
free diet (GFD) or remains untreated, the degree of
compliance with the GFD in treated subjects and
preferably also the duration between development of
gluten hypersensitivity and initiation of treatment, as
all these factors might influence development of long-
term complications.
Revision of diagnostic criteria
In 1990, ESPGHAN revised its former diagnostic criteria
for CD laid down in 1970.19 Requirements remaining
mandatory for the diagnosis are: (i) the finding of
villous atrophy with hyperplasia of the crypts and
abnormal surface epithelium, while the patient is eating
adequate amounts of gluten and (ii) a full clinical
remission after withdrawal of gluten from the diet. The
finding of circulating IgA antibodies to gliadin, tissue
transglutaminase (tTG) or endomysium at the time of
diagnosis and their disappearance on a GFD adds weight
to the diagnosis. The growing contribution of serology,
together with the recognition of a wider spectrum of
histological changes and the contribution by genetic
tests, demonstrates the necessity to move on to a revised
diagnostic approach. For this purpose, we need not only
epidemiological studies aimed at assessing the risk
related to gluten ingestion in the different groups of
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patients (symptomatic, silent, potential) but also more
information on the genetic make-up and on the immu-
nological mechanisms leading to the full disease. The
complete identification of genes involved is needed so
that genetically susceptible individuals can be identified
and the risk of developing the disease can be precisely
assessed. The involvement in the same patient of the
different branches of the immune response to gluten –
adaptive and innate – needs to be assessed, as both
probably are necessary for a full expression of the
disease. This information will have a strong impact on
the clinical categorization of patients and even on the
definition of CD.
As far as clinical aspects of CD are concerned, major
issues in need of investigation are reported in Table 1.
TREATMENT
Who should be treated?
As far as the need for a GFD, it is quite clear that in a
vast majority of cases, such a diet leads to disappear-
ance of clinical symptoms, recovery of normal duode-
nal histology, disappearance of the serological signs of
CD and prevention of CD complications, although
it should be noted that there are no large RCT evalu-
ating the effect of GFD. Furthermore, the criteria for
remission are not clearly defined. A recent Italian
study confirms histological normalization in 74.1%
of paediatric cases, but only in 17.5% of adults.20
To assess health improvement after initiation of CD
treatment is relatively easy in patients with clinical
symptoms of the disease, but difficult in persons with
asymptomatic CD identified by screening such as in
first degree relatives of CD patients or subjects with
Down’s syndrome or type 1 diabetes. In addition, it is
not known if patients with untreated CD detected
after screening have the same long-term risk of
complications as patients with clinically diagnosed CD.
Moreover, little is known about the health risks of
those untreated with minor enteropathy, maybe silent
from a clinical point of view. In addition, it seems that
some CD patients may develop tolerance for gluten
later in life.18, 21, 22 Thus, more knowledge about the
mechanisms involved in the re-gaining of tolerance
is necessary to identify those patients that may not
need a GFD during their whole life. Well designed
follow-up collaborative studies between epidemio-
logists and clinicians are needed to elucidate all these
aspects.
Improving health care in CD patients
Adherence to a GFD may have negative nutritional
consequences,23, 24 but regular dietary controls are
reported only by a minority of the CD patients,24 with
large variations between countries. Prospective collab-
orative studies between dieticians and clinicians are
needed to investigate if better dietary support is neces-
sary to achieve an ongoing satisfying management
and to prevent long-term complications in this group
of patients.
Table 1. Clinical aspects of coeliac disease – major issues in need of investigation
Elucidation of the clinical and
histological spectrum
Increase in awareness of the health professionals in identifying CD by case finding.
Pathomechanisms underlying the different manifestations such as malabsorption and
autoimmunity
The role of tissue deposited IgA antitransglutaminase antibodies
Exploring the autoimmunity
spectrum
Identification of the whole spectrum of gluten-related autoantibodies
Gluten ingestion and risk of autoimmunity
Infant feeding patterns and risk of autoimmunity
Definition of the natural history Timing of appearance of CD-related autoantibodies and progression of intestinal
damage
Environmental factors conditioning the severity of the histological and clinical
presentation
Revision of diagnostic criteria Identification of genes and risk assessment
Immunological markers of innate and adaptive immunity
New diagnostic approaches based on immunology and genetics, enabling
performing biopsy and histology only in selected cases
CD, coeliac disease.
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Gluten threshold for gluten-free food
In 1982, the Codex Alimentarius Committee on Nutri-
tion and Food for Special Dietary Uses (CCNFSDU) set
the limit of gluten allowed in raw materials to produce
gluten-free food to 0.05 g nitrogen per 100 g dry mat-
ter. Recently, an R5 ELISA method for gluten ⁄gliadin
determination in food has become available based on
a monoclonal antibody reacting with the specific glia-
din pentapeptide QQPFP. This method shows a sensi-
tivity and limit of detection (1.5 ppm gliadin), which
is superior to older methods.25 At the moment, provi-
sional levels of (20 ppm gluten) for food gluten-free
by nature and (200 ppm) for food rendered gluten-free
(wheat starch-based products) have been accepted
[Draft Revised Standard for gluten-free foods (ALIN-
ORM 04 ⁄27 ⁄26) CCNFSDU]. The problem is that this
standard refers to the amount contained in a food item
but not to the amount of food that can be taken by a
person who is sensitive to it. Recently, the results of a
prospective, double-blind, placebo-controlled trial per-
formed to establish the safe gluten threshold for
patients with CD have shown that most patients with
CD should ingest less than 50 mg gluten per day.26
Studies linking the best available analytical detection
of gluten to the clinical applications and relevance in
the treatment of the patients should be performed. An
important aspect in this respect is that it is not known
to what extent the threshold of tolerance for gluten
ingestion varies between different CD patients. Also, it
is not yet clear if it is constant over time in a certain
patient, or varies over time merely by a change in age
or also by influence of other environmental factors.
Collaborative studies should be performed to elucidate
these mechanisms and to define the threshold of toler-
ance for gluten in different CD individuals with differ-
ent genetic make-up and at different ages.
Oats toxicity
Currently, CD treatment is almost the same as it has
been for more than half a century: a life-long strict
GFD with exclusion of gluten from wheat, rye and
barley. In general, oats are safe both for adults and for
children with CD.27 One concern about oats consump-
tion in a GFD is the frequent contamination of oats
with gluten during the harvesting and milling
process.28 In addition, some CD patients have avenin-
reactive mucosal T cells, although not all these have
concurrent enteropathy.29 In conclusion, it seems wise
to add oats only when the GFD is well established, so
that possible adverse reactions can be readily identi-
fied by a strict clinical follow-up. Studies directed to
obtain commercial uncontaminated oats safe for peo-
ples with CD are needed. Moreover, further studies are
necessary to assess immunogenicity and toxicity of
different oat cultivars.30
Development of new foods for CD patients
Gluten is a complex mixture of proteins that contain a
multitude of immunogenic peptides. There are many
wheat varieties and not all of which appear to be
equally toxic to patients.31 Recently, first attempts
have been made to quantify the toxicity of a range of
bread wheat and pasta wheat varieties and of species
that contain only one of the three genomes of bread
wheat. Using specific T-cell clones and monoclonal
antibodies, the results demonstrate that large quantita-
tive differences exist in the presence of toxic gluten
peptides, with some cultivars completely lacking par-
ticular harmful peptides.31 Large-scale genomics and
proteomics wheat research will elucidate the genetic
and allelic diversity of the wheat gluten genes and
proteins. Alternative strategies include the application
of RNA interference to silence specifically those gluten
genes that contain CD-toxic epitopes, as well as the
construction of hexaploids from diploid wheat species
of proven low CD-toxicity. The main problem will be
to eliminate or avoid CD epitopes, while retaining the
industrial quality of the material. By linking these data
to toxicity data, it will be possible to evaluate the fea-
sibility of marker-assisted breeding to produce or
select nontoxic wheat varieties. This offers new oppor-
tunities for the generation of safer wheat strains. In
addition, other cereals that do not contain harmful
gluten or gluten-like molecules such as the Ethiopian
cereal tef can be selected.32 Future projects on selec-
tion and cultivation of traditional or biotechnologi-
cally modified gluten-free cereal variants, such as tef
or oats, provide great promise to coeliac patients,
although the economic feasibility and the time horizon
of introducing these new variants may have possibly
been judged rather optimistically.
New treatments
A GFD is at present the only possible treatment for CD
patients, but there are a number of drawbacks to a life-
long diet. At present, there are several options that can
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be explored. Because of the high proline content, gliadin
peptides are highly resistant to digestive processing by
pancreatic and brush border proteases.33 Enzyme sup-
plement therapy using bacterial prolyl endopeptidases
has been proposed to promote complete digestion of
cereal proteins and destroy T-cell multipotent epi-
topes.34–36 The efficacy of this approach needs to be
assessed in in vivo studies. Other promising areas
include modulation of intestinal permeability,37
preventing gliadin presentation to T cells by blocking
HLA-binding sites, use of tTG inhibitors,38 and
assessing the use of interleukines and other immuno-
modulatory strategies to promote tolerance.39–41
Evidence that gluten toxicity is not dependent only on
T-cell recognition is growing; activation of innate
immunity has been demonstrated in CD42, 43 and anti-
bodies to IL-15 have been proposed to treat refractory
CD.44 Nevertheless, one should realize that usually CD is
a benign disease and dietary treatment is safe although
strenuous. An immunomodulatory approach will need
to have a safety profile equivalent to that of the GFD,
but with the advantage of increased compliance.
Moreover, there are not only theoretical problems to
solve but it is also crucial to consult the patients for
their demands and for their acceptability of
medications that may ultimately replace GFD. The
cost-effectiveness of treatment alternatives to GFD
should be assessed. At the moment, many of the com-
mercial activities to develop new treatments for CD
are based outside Europe. To enable also European
researchers to translate their results to outcomes for
patients, it is important that such commercial activities
and investments are increased in Europe and that col-
laborative studies and alliances between industry and
researchers from in and outside Europe are stimulated.
As far as treatment of CD is concerned, major issues
in need of investigation are reported in Table 2.
PREVENTION
Infant-feeding practices
As CD has a multifactorial aetiology, it is likely that
environmental factors contribute to CD development
throughout the life span;45 however, so far, research
has mainly focused on the infancy period and early
feeding. Thus, it has been suggested that primary pre-
vention might be attained through favourable infant-
feeding practices,45, 46 thereby increasing the chance
for infants to develop oral tolerance to gluten and
possibly also promoting the maintenance of tolerance
throughout life.
Table 2. Treatment of coeliac disease – major issues in need of investigation.
Decision on treatment criteria Long-term health risks of silent and potential coeliac disease and the impact of
early diagnosis
Natural development of permanent or transitory gluten tolerance in CD cases
Improvement in health care
and quality of life
Nutritional consequences of the gluten-free diet and advantages of a better dietary
support
Food labelling, availability of gluten-free foods and awareness of the disease.
Development of safe and new
foods
Oats toxicity
Threshold of tolerance to gluten
Genomics and proteomics of different wheat cultivars and implementation of
traditional or biotechnologically modified gluten-free cereal variants
Exploring treatment alternatives Enzyme supplements therapy
Reestablishment of the intestinal barrier against gluten entry
Blocking of gliadin presentation by HLA blockers and tTG inhibitors
Cytokines and anticytokines such as IL10, anti-IFNc and anti-IL15
Reestablishment of tolerance (modified gluten peptides, nasal tolerance)
Development of a relevant animal model
Explore the cost-effectiveness of alternative treatments
Assess the demand from patient support group of the nature of alternative
treatment to GFD
Strategies to stimulate collaborative studies and alliances between
industry and researchers from in and outside Europe
CD, coeliac disease; HLA, human leukocyte antigen; tTG, tissue transglutaminase; GFD, gluten-free diet.
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A recent meta-analysis of observational case-
referent studies has concluded that breastfeeding
during the introduction of dietary gluten and increas-
ing duration of breastfeeding were associated with
reduced risk of developing CD.47 However, it is not
clear from the primary studies whether breastfeeding
provides a true protection in a short- or long-term
perspective or merely modifies the symptoms with
delayed diagnosis as a result. In a recent prospective
observational study including only children with a
high risk for autoimmune disease, no protective effect
of prolonged breastfeeding was observed with respect
to CD autoimmunity.16 The true impact of breastfeed-
ing on the development of CD remains controversial.
A possibility is that differences in gut microbiota
between breastfed and formula fed infants play a role
in the protection given by breast feeding. Long-term
prospective cohort studies in high-risk children for CD
are required to investigate further the relation between
breastfeeding and CD.
There may be an age interval during which humans
acquire increased ability to develop oral tolerance to a
newly introduced antigen, an option that needs to be
explored also with respect to gluten and CD risk. Age
of the infant at introduction of dietary gluten did not
remain an independent risk factor in a case-referent
study adjusting for differences in other exposures, i.e.
breastfeeding status and varying amounts of gluten
given during introduction, although with the limita-
tion that only the first year of life was evaluated.48 In
one prospective observational study, it was examined
whether timing of introduction of gluten to infants
diet influences subsequent onset of CD autoimmuni-
ty.16 Among HLA-DR3-positive children, introduction
of gluten foods by age 3 months was associated with
a fivefold increased risk for CD autoimmunity com-
pared with exposure at age 4–6 months. Exposure at
or after age 7 months was also associated with a
slightly increased risk for CD autoimmunity compared
with exposure at 4–6 months. These data suggest that
both early (£3 months after birth), and late
(>7 months after birth), introduction of gluten may
increase the risk of CD and should be avoided. The
strength of this study is its prospective design; how-
ever, it has several limitations as the small number of
subjects in whom the outcome measures occurred, the
use of CD autoantibodies as a surrogate for biopsy-
diagnosed CD and also the amount of gluten during
introduction was not assessed and thus remains as a
potential confounder.
The dose of dietary antigen ingested during infancy
may influence whether or not oral tolerance develops.
Interestingly, Sweden has experienced an epidemic of
CD in children below 2 years of age, where the abrupt
fourfold rise in incidence was preceded by a twofold
increase in the average daily consumption of gluten
and later, the abrupt fall in incidence coincided with a
decreased consumption by one-third.46, 49 Moreover, a
Swedish population-based incident case-referent study
demonstrated, for the first time, that introduction of
gluten-containing foods in large amounts compared to
small or medium amounts was an independent risk
factor for CD development (adjusted OR = 1.5, 95% CI:
1.1–2.1).48 Thereafter, an interaction between HLA-DQ
expression and the available number of T-cell stimula-
tory gluten peptides was also demonstrated, suggesting
a quantitative model for CD development.50 It is, how-
ever, not clear whether there is a direct dose-response
effect or a threshold effect.
Given the importance of feeding pattern in the first
year of life as environmental factors contributing to
CD risk, the prevention strategies we can envisage
today are mainly based on dietary advice. Data avail-
able suggest that breastfeeding must be encouraged.
Prospective studies are very much needed to assess the
importance of time and dose of gluten at its introduc-
tion in infants’ diet.
Pro- and prebiotics in infancy
In other conditions characterized by a deranged
immune response of the mucosal immune system,
attention has been given to the possible role of intesti-
nal bacteria. Probiotics have been suggested to influ-
ence immune development and type of immune
response.51 Therefore, it could be envisaged that probi-
otics may influence the type of immune reactivity to
gluten in CD subjects; however, at present, there are
no studies that have addressed this issue. In any case,
the possibility of introducing other molecules to
infants during weaning, which could drive the immune
response to gluten proteins towards tolerance, is worth
exploring.
Infections
Infectious episodes could potentially contribute to the
aetiology of CD as they might increase gut permeabil-
ity with increased antigen penetration and ⁄or may
drive the immune system towards a TH1-type response
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typical for CD. Moreover, rod-shaped bacteria adhering
to the intestinal mucosa and differences in the glyco-
sylation structure of the mucosa were recently demon-
strated for untreated and treated CD patients,52
suggesting a possible defect in innate immunity. The
Swedish case-referent study found that children who
experienced three or more infectious episodes before
six months of age had an increased risk for CD before
2 years of age (adjusted OR = 1.4, 95% CI: 1.0–1.9),
also after adjusting for differences in infant feeding
including breastfeeding.45
Two recent papers have attracted the attention on
the possible relationships between rotavirus infection
and CD.53, 54 A peptide sequence, specifically recog-
nized by sera from untreated coeliac subjects, sharing
a high degree of homology with the rotavirus serotype
1 major neutralizing protein VP7, has been identified.
Furthermore, epidemiological observations on the sea-
sonal pattern of incidence of CD have sustained the
hypothesis of a viral infection triggering the disease.55
Rotavirus, as appears from these two recent papers, is
a good candidate. The observations pointing to a pos-
sible role played by rotavirus in the pathogenesis of
CD open a new perspective for prevention strategies in
this era of rotavirus vaccination. Further studies are
needed to exclude any risk of inducing autoantibodies
by mechanisms of molecular mimicry.
A life-course approach
It is likely that CD development, after the infant per-
iod, is also influenced by environmental factors,
including life-style factors.45 CD has several features
in common with autoimmune diseases, although
dependent on gluten exposure, and during the life
course an increasing proportion of the population can
be expected to be affected. Thus, the search for such
causal factors, which exhibit their effect during differ-
ent periods of the life span, should be intensified. This
approach would most likely lead to the identification
of a large range of entry points for primary preven-
tion45
General or targeted preventive advice?
Preventive advice is the most effective if disseminated
widely to the general population instead of approach-
ing only certain risk groups. However, this strategy
is only ethically acceptable, although the advice
of no harm to anyone benefits the risk groups most.
Recommending breastfeeding of infants benefits all
and is likely to be even more important for infants
with an increased risk for CD as reflected by a first
degree relative with the disease. Thus, such advice can
be given generally, without targeting the CD families.
However, other preventive strategies may need to
target high-risk subjects. First degree relatives of CD
patients, as they are clearly recognized as a genetically
susceptible group, represent an important target.
Although they carry an approximate risk of 5–10%, it
has become clear recently that in their context, there
are individuals with a very high risk (up to 30%) on
the basis of their HLA-DQ genotype.56 With the
increasing knowledge of other genetic factors of sus-
ceptibility, also of non-HLA genes, it will be possible
to give to each individual a profile of risk and then to
identify those most suitable to an active intervention
aiming at prevention of CD.
As far as primary prevention of CD is concerned,
major issues in need of investigation are reported in
Table 3.
PUBLIC HEALTH
Public health implications
Over the last decades, CD has emerged as a public
health problem,57–60 being fairly common and mostly
undiagnosed, and thereby also untreated. Many of the
undiagnosed individuals simply accept a chronic state
of vague ill-health as normal with reduced well-being,
health and also reduced working capacity, while others
spend time and resources chasing better health. A
broad spectrum of symptoms vary considerably
between individuals and within a single individual
over time and are therefore often not thought of as
being caused by CD, which results in unnecessary
health examinations in addition to delayed or even
missed diagnoses. Once diagnosed, the recommended
GFD improves well-being and health for almost all
coeliacs;61, 62 however, dietary compliance in everyday
life is a challenge that requires commitment and sup-
port. Higher household costs for foods are incurred by
the use of specially produced gluten-free food items
and also the cooking is more time-consuming as
readymade foods often are gluten-containing and
therefore not suitable. Thus, CD has considerable nega-
tive impact on the well-being and health of the public
and also has negative economical consequences for
both affected individuals and society as a whole.
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Health-related quality of life
HRQOL is a multidimensional concept encompassing
physical, emotional, social and cognitive domains,
variable over time and is getting increasing attention
in medical and health care settings. What matters in
HRQOL is the way patients feel about their function-
ing, not their functioning itself.63 A majority of CD
subjects, symptomatic as well as screening-detected,
report improved HRQOL after initiation of treatment
with a GFD.61, 62 Interestingly, the HRQOL in treated
CD subjects seems to vary between countries, e.g. in
the Netherlands and Canada, it is reported to be com-
parable with the general population,63, 64 while
decreased as reported from an Italian study.65 In a
Swedish 10-year follow-up study of CD treated adults,
the females scored lower and the males higher com-
pared with gender-matched controls.66 However, meth-
ods to measure HRQOL vary between the studies,
which restrict comparability.
HRQOL needs to be measured by standardized
HRQOL-CD questionnaires,67 which will allow better
comparisons between countries, while also enabling
researchers and clinicians to determine better the con-
sequences of CD and its treatment on the daily life of
affected persons. By using also the EQ 5D instrument
covering five dimensions of health, i.e. mobility, self-
care, usual activities, pain ⁄discomfort and anxi-
ety ⁄depression, and containing the EQ 5D Visual
Analogue Scale,68 the results can be converted into a
weighted health state index to be used to generate
quality-adjusted life years (QALY). Also, to facilitate
meaningful comparisons, it must be clearly described
what group of CD subjects are included, i.e. children or
adults, cases detected as a result of symptoms or
screening, untreated or treated, and for the latter group
also an estimate of compliance with the GFD. Impor-
tantly, collaborative studies involving representatives
of the food industry, food policy makers and health
care providers are needed to investigate, among many
initiatives, whether the HRQOL in CD subjects can be
improved by increased availability of gluten-free foods,
improved food labelling and better education of physi-
cians and dieticians about CD and the GFD.69
Is mass-screening a wise use of resources?
It is crucial, from a public health perspective, to
increase the detection rate of CD. Since the 1980s,
serological markers are available, which lately also
can be supported by HLA-typing and in future by
non-HLA risk factors. In primary care, CD detection
rate can be considerably improved by increased aware-
ness among health professionals.70–72 Thus, active
case-finding among patients who seek medical advice
should be intensified. However, mass screening for CD,
i.e. screening of the general population, would be the
only way to identify a majority of people with CD.
Importantly, most of the World Health Organization’s
criteria required for implementation of a mass screen-
ing program, are fulfilled for CD, i.e. it is a fairly com-
mon disease with an effective treatment, it is often
unrecognized with extensive negative health conse-
quences and serological markers with a high predictive
value are available,73 but still mass screening is a con-
troversial issue.74
Table 3. Primary prevention of coeliac disease – major issues in need of investigation
Determining the role of breastfeeding Long-term effects of breastfeeding
The molecular basis for the suggested protective effect of breast milk
Determining the role of timing and dose
of gluten during introduction
Optimal age for introducing gluten
Timing in relation to breastfeeding and infectious episodes
Optimal dose of gluten and pattern for introduction
Mucosal immune response at the time of gluten introduction
Exploring the role of life style factors in
children and adults
A life-course approach to CD development, thus, a search for potentially
contributing causes, also after infancy
The role of daily gluten intake
The wide range of potential causal environmental factors such as
infections, vaccinations, etc
Exploring the option of general and
targeted prevention
Advice to the general population vs. genetically identified high-risk subjects
Public health impact of different preventive strategies
CD, coeliac disease.
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To be implemented, mass-screening for CD should
be defendable from a health economy point of veiw,75
and such evaluations are called for.76–79 Both costs
and savings related to CD diagnosis and treatment
should be estimated. The screening procedure for CD
and also the following case ascertainment, as well as
the subsequent GFD in verified cases, are related to
certain costs. However, adequate treatment of CD cases
should reduce complications and the need for future
health care, and most likely also result in increased
productivity, these being factors which should also be
considered. Long-term health consequences also
should be evaluated in relation to degree of compli-
ance with the GFD, as it has been suggested that
screening detected CD persons tend to be less compli-
ant with the GFD, compared with those diagnosed
after actively seeking health care.80 However, non-
economical aspects such as changes in HQOL should
also be taken into account, preferably with the EQ-5D
instrument, as the result can be assessed in QALYs.
This will allow for an estimate of costs per QALY
gained by the increased CD case detection and sub-
sequent treatment with a GFD, which then allows
comparisons with the cost-effectiveness of other com-
peting health interventions.
Willingness to pay (WTP) is a complementary health
economy method that could be used to evaluate CD
mass-screening. Before the screening for CD, the par-
ticipants are given a detailed scenario, including the
screening and diagnostic procedure, the risk for CD,
and possible future complications, and also gains of
being diagnosed. A hypothetical question is posed
about their maximum WTP for the CD screening
procedure. The WTP then represents the so called
intangible costs and benefits, i.e. the value of
improved health both in the shorter and in the longer
perspectives, the inconvenience and discomfort of fol-
lowing a restricted diet, and the worry and anxiety
that the screening may cause.
Global occurrence
The global occurrence of CD and changes over time
need to be determined and this requires country cross-
sectional screening studies involving age- and gender-
representative samples of the populations and repeated
screening over time. Finding variations in prevalence,
and exploring reasons behind these, will increase our
understanding of the CD aetiology. Such mapping also
facilitates adequate health care planning including
decisions whether or not to give priority to increase
detection rate of CD and what strategy to use, i.e.
active case-finding initiatives or screening of certain
high-risk groups, or even the general population. Also,
the overall economic consequences of CD in a specific
country or region can be estimated.
Incidence registers, to which all newly diagnosed CD
cases in a well-defined population are continuously
reported, would enable analyses of temporal relation-
ships between changes in environmental factors and
incidence rates and thereby depict potential aetiological
factors. Such longitudinal efforts would also provide
the basis for long-term follow-up of coeliac subjects
and facilitate in-depth studies and increase our under-
standing of the aetiology and natural history.
As far as public health aspects of CD are concerned,
major issues in need of investigation are reported in
Table 4.
Table 4. Public health aspects of coeliac disease – major issues in need of investigation
Estimating consequences with
respect to health related quality
of life
Standardized instruments for measuring health related quality of life in untreated
and treated subjects
Consequences of CD and its treatment on the daily life of affected persons.
Public health impact of CD
Evaluating consequences of
mass-screening
Active-case finding and mass-screening strategies
Costs and savings related to diagnosis and treatment
Gains in health related quality of life estimated as QALYs
Costs per QALY gained and comparison with other health interventions
Determining the global
occurrence
Cross-sectional screening of age- and gender-representative population samples
globally to facilitate health care planning
Incidence registers for epidemiological surveillance and to be used as a basis
for aetiological and long-term follow-up studies
CD, coeliac disease; QALY, quality-adjusted life year.
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CONCLUSIONS
While addressing the public health problem of CD, the
overall goal should be to improve HQOL of the Euro-
pean population by implementing primary prevention
strategies, early diagnosis and improved treatments for
CD.
It is urgent to increase the awareness of CD as a pub-
lic health problem through educational efforts aiming
at the public as well as health professionals. A likely
consequence would be an increased CD case detection
rate and improved support for those diagnosed. Also,
other strategies for effective case-finding in high-risk
families and even mass screening efforts in populations
should be explored to decrease the large proportion of
undiagnosed and untreated CD subjects. Such efforts
should include evaluation of short- and long-term
consequences both for participating individuals and for
society, also considering health economy aspects.
Moreover, the magnitude of the CD problem world-
wide and trends over time should be established taking
into account distribution with respect to age, gender
and different high-risk groups. The impact of CD on
public health with respect to HQOL and burden of
morbidity and mortality should be determined. While
doing so, CD of different types should be considered
as their health consequences might differ for symp-
tomatic, silent, latent and potential cases.
New treatment strategies need to be developed.
Notably this includes a standardized labelling of
gluten-free foods and meeting the needs of the people
affected by CD with safe, palatable and affordable
foods. HQOL of CD subjects should be improved by
developing novel therapeutic modalities. The designed
strategy should include the development of an animal
model of gluten sensitivity to analyse novel treatments
for CD. Expected results are the identification of nutri-
tional, immunomodulatory and biochemical strategies
useful to treat CD subjects successfully.
The option of primary prevention should be fully
explored, which requires combined epidemiological,
clinical and basic scientific research efforts. Increased
knowledge is needed on the potential impact of envi-
ronmental factors including life-style factors and also
genetic determinants and immunological pathways.
Such studies should also consider the importance of
gene–environment interactions in the development of
CD. It is interesting to know that notwithstanding
minor differences caused by the different perspective
(North American and European) between the present
manuscript and the NIH Consensus Statement on Coe-
liac Disease (http://consensus.nih.gov/cons/118/118cdc_
intro.htm), there is almost a complete overlap as far as
the recommendations for future research are concerned.
To achieve these goals and have a significant impact
on the public health problem of CD, a collaboration of
the stakeholders is fundamental, including research
and patient associations as well as industries within
both diagnostics and food production.
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